APCCC 2024 | 5-year follow up of short-course abiraterone and ADT for high-risk prostate cancer

Andrew Armstrong, MD, Duke University, Durham, NC, discusses the five-year outcomes of the AbiRT trial (NCT05177042), which evaluated a six-month course of abiraterone acetate, prednisone, and androgen deprivation therapy (ADT) combined with curative-intent radiation in patients with high-risk prostate cancer. The study demonstrates that a significant majority of patients remain in remission with minimal toxicities and successful recovery of testosterone levels within a year. This promising short-course therapy offers a potential new approach for managing high-risk prostate cancer. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.